Identifying Genes Linked to Ovarian Cancer Drug Resistance
Author Information
Author(s): Roberts D, Schick J, Conway S, Biade S, Laub P B, Stevenson J P, Hamilton T C, O'Dwyer P J, Johnson S W
Primary Institution: University of Pennsylvania Cancer Center
Hypothesis
Understanding the molecular basis for platinum drug sensitivity/resistance is necessary for the development of new drugs and therapeutic regimens.
Conclusion
The study identified that increased Stat1 expression is associated with decreased sensitivity to certain platinum drugs in ovarian cancer cells.
Supporting Evidence
- Increased Stat1 expression was associated with decreased sensitivity to cisplatin and AMD473.
- Functional studies showed that inhibiting Jak/Stat signaling increased sensitivity to AMD473.
- Correlation analysis revealed a significant association of Stat1 expression with decreased sensitivity to cisplatin.
Takeaway
Researchers looked at how certain genes affect the ability of ovarian cancer cells to resist treatment with platinum drugs, finding that one gene, Stat1, makes cells less sensitive to these drugs.
Methodology
The study used cDNA microarray screening to evaluate the expression of approximately 4000 genes in 14 ovarian cancer cell lines.
Potential Biases
The study may not account for all potential mechanisms of drug resistance due to the diversity of the cell lines used.
Limitations
The overall number of cell lines examined relative to the large amount of expression data obtained may limit the findings.
Participant Demographics
The cell lines were derived from patients who were either untreated or treated with platinum-based chemotherapy.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website